Sai Parenteral's

Why is Sai Parenterals Ltd falling/rising?

As of 04-Aug, Sai Parenterals Ltd's stock price is at 531.25, down 4.26% and underperforming its sector. The stock has shown short-term weakness, trading below several moving averages, and investor participation has decreased significantly.

As of 04-Aug, Sai Parenterals Ltd's stock price is falling, currently at 531.25, which reflects a decrease of 23.65 or 4.26%. This decline is evident as the stock has underperformed its sector by 4.44% today. The stock opened with a loss of 2.48% and reached an intraday low of Rs 530, marking a drop of 4.49%. Additionally, the stock has experienced a trend reversal, falling after two consecutive days of gains.<BR><BR>Investor participation has also decreased, with delivery volume on 03 Aug falling by 20.36% compared to the 5-day average. Although the stock is trading above the 100-day and 200-day moving averages, it is below the 5-day, 20-day, and 50-day moving averages, indicating a short-term weakness. Overall, these factors contribute to the stock's current downward movement.

Which are the latest news on Sai Parenteral's?

When is the next results date for Sai Parenterals Ltd?

The next results date for Sai Parenterals Ltd is 11 August 2026.

The next results date for Sai Parenterals Ltd is scheduled for 11 August 2026.

What does Sai Parenteral's do?

Sai Parenterals Ltd is a small-cap company in the Pharmaceuticals & Biotechnology industry, specializing in parenteral products. As of March 2026, it reported net sales of ₹57 Cr and a net profit of ₹10 Cr, with a market cap of ₹2,479 Cr.

Overview: <BR>Sai Parenterals Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History: <BR>Sai Parenterals Ltd was originally incorporated as 'Sai Parenteral's Private Limited' in 2001. The company transitioned to a Public Limited Company and changed its name to 'Sai Parenteral's Limited' on January 17, 2022. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 57 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 10 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 2,479 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 172.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.17 <BR>Return on Equity: 2.91% <BR>Price to Book: 5.04<BR><BR>Contact Details: <BR>No Company Details Available <BR>Registrar Address: Not available.

How big is Sai Parenteral's?

As of 10th June, Sai Parenterals Ltd has a market capitalization of 2,479.00 Cr, with recent Net Sales of 294.08 Cr and a Net Profit of 6.50 Cr for the quarters ending March 2026 and December 2025.

As of 10th June, Sai Parenterals Ltd has a market capitalization of 2,479.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest two quarters, the company reported Net Sales of 294.08 Cr and a Net Profit of 6.50 Cr. This reflects the financial performance for the quarters ending March 2026 and December 2025.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 93.67 Cr and Total Assets valued at 271.86 Cr.

Who are the peers of the Sai Parenteral's?

Sai Parenteral's peers include Unichem Labs, Novartis India, Solara Active, and others, with varying management risk and growth ratings. Venus Remedies leads in 1-year returns at 270.28%, while Dishman Carbogen has the lowest at -38.51%.

Peers: The peers of Sai Parenteral's are Unichem Labs., Novartis India, Solara Active, Dishman Carbogen, Morepen Labs., Kwality Pharma, Venus Remedies, Hikal, Indoco Remedies, and Sakar Healthcare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Novartis India, Venus Remedies, and the rest have Average management risk, including Unichem Labs., Morepen Labs., Kwality Pharma, Hikal, Indoco Remedies, and Sakar Healthcare. Below Average management risk is found at Solara Active and Dishman Carbogen. Growth is rated as Excellent for Novartis India, Venus Remedies, and Kwality Pharma, while Good growth is seen at Unichem Labs. and Dishman Carbogen. The rest, including Solara Active, Morepen Labs., Hikal, Indoco Remedies, and Sakar Healthcare, exhibit Below Average growth. Capital Structure is Excellent for Novartis India, Morepen Labs., and Kwality Pharma, while Good is seen at Unichem Labs. The rest, including Solara Active, Dishman Carbogen, Hikal, Indoco Remedies, and Sakar Healthcare, have Below Average capital structure.<BR><BR>Return Snapshot: Venus Remedies has the highest 1-year return at 270.28%, while Dishman Carbogen has the lowest at -38.51%. Sai Parenteral's 1-year return is not available for comparison. Additionally, Hikal and Dishman Carbogen have negative six-month returns.